Provided by Tiger Trade Technology Pte. Ltd.

REIN THERAPEUTICS INC

0.7570
+0.00430.57%
Volume:98.03K
Turnover:75.14K
Market Cap:64.75M
PE:-0.45
High:0.7910
Open:0.7600
Low:0.7543
Close:0.7527
52wk High:2.18
52wk Low:0.6940
Shares:85.54M
Float Shares:65.83M
Volume Ratio:1.56
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6800
EPS(LYR):-1.9600
ROE:-96.42%
ROA:-21.02%
PB:6.35
PE(LYR):-0.39

Loading ...

Rein Therapeutics Faces NASDAQ Delisting Notice After Shares Trade Below $1 Bid Threshold

Reuters
·
Aug 28

Rein Therapeutics - Enrolling Patients in Phase 2 Renew Trial for Lti-03; Interim Data Expected H2 2026

THOMSON REUTERS
·
Aug 20

Rein Therapeutics Receives U.S. FDA Fast Track Designation for Lti-03 in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
Aug 20

Rein Therapeutics Releases Corporate Presentation on LTI-03 Idiopathic Pulmonary Fibrosis Program

Reuters
·
Aug 20

Rein Therapeutics Inc Reports Results for the Quarter Ended March 31 - Earnings Summary

Reuters
·
Aug 14

Rein Therapeutics Inc Q2 Income from Operations USD -6.076 Million

THOMSON REUTERS
·
Aug 14

Rein Therapeutics Inc Q2 Net Income USD -6.375 Million

THOMSON REUTERS
·
Aug 14

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 14

Rein Therapeutics Q2 FY26 Net Loss Narrows to $6.38 Million; Operating Loss Improves 11.57% to $6.08 Million

Reuters
·
Aug 14

Rein Therapeutics Inc Expected to Post a Loss of 17 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 06

Rein Therapeutics Publishes First-in-Human LTI-03 Idiopathic Pulmonary Fibrosis Data in Nature Communications

Reuters
·
Aug 04

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

GlobeNewswire
·
Aug 04

Rein Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Jul 22

Rein Therapeutics Releases Update on Phase 2 RENEW Trial Enrollment Expansion

Reuters
·
Jul 21

Rein Therapeutics Announces Phase 2 Renew Trial NOW Enrolling Across All Five Countries

THOMSON REUTERS
·
Jul 21

Rein Therapeutics initiated with a Buy at Maxim

TIPRANKS
·
Jul 20

Rein Therapeutics Inc : Maxim Group Initiates Coverage with Buy Rating; Price Target $4

THOMSON REUTERS
·
Jul 20

Rein Therapeutics expands Phase 2 RENEW trial of LTI-03 in IPF into UK

Reuters
·
Jun 11

Rein Therapeutics Expands Phase 2 Renew Trial Into United Kingdom

THOMSON REUTERS
·
Jun 11